This PDF file includes:

• Fig. S1. No increase in mature AMs following the subcutaneous administration of rGM-CSF (20 ng) to LPL^−/− neonatal pups on DOB, PND1, and PND2.
• Fig. S2. No disruption of alveolarization observed after intranasal neonatal rGM-CSF therapy.
• Fig. S3. Increased SP-D in LPL^−/− PND3 neonatal pups.

Download PDF